PMA device
Optune Gio
Novocure, GmbH · Stimulator, Low Electric Field, Tumor Treatment (NZK, Class III) · First FDA decision Oct 30, 2024, newest Jun 4, 2026Brain tumors
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
2
Naming "Optune Gio"
MAUDE reports
608
Brand "Optune Gio", since 2015
PubMed studies
2
Mentioning "Optune Gio"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Optune Gio
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Optune GioPMA supplement
P100034-S042 · Decided Jun 4, 2026 · 247 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
- Optune GioPMA supplement
P100034-S033 · Decided Oct 30, 2024 · 350 days after receipt · Normal 180 Day Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Tumor Treatment Field Therapy (TTFT)Local determinationIn effectL34823CGS Administrators, LLCUpdated Feb 21, 2020
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Positron Emission Tomography for Initial Treatment Strategy in Solid Tumors and MyelomaNational analysisReview closedCAG-00181R3Updated Sep 21, 2026
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Treatment of Motor Function Disorders with Electric Nerve StimulationNational determinationOn the books160.2Updated Aug 17, 2023
- Blood Brain Barrier Osmotic Disruption for Treatment of Brain TumorsNational determinationOn the books110.20Updated Mar 17, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "Optune Gio", any status and sponsor, newest update first.
University of FloridaAcademic, hospital or other
NCT06558214 · 20 participants (planned) · Start Dec 10, 2024 · Primary completion Oct 2029
Device: Optune GIO®; NeuroBlate® · For: Recurrent Glioblastoma
Sites: Gainesville, Florida
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruiting
ImmunityBio, Inc.Not on our public-company list
NCT06061809 · 34 participants (planned) · Start Aug 7, 2024 · Primary completion Dec 31, 2029
Device: Tumor Treating Fields (TTFields, 200 kHz) · For: Glioblastoma
Sites: El Segundo, California; Fullerton, California; Newport Beach, California · 4 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Optune Gio", and for the whole product code for context.
This brand
608 reports: 1 malfunction, 605 injury, 2 death
Whole product code NZK
813 reports: 1 malfunction, 806 injury, 6 death
Newest reports for this brand
- Optune GioInjury
3010457505-2026-00897 · Received Oct 28, 2026 · Event dated Sep 22, 2026
Device type: Stimulator, Low Electric Field, Tumor Treatment (NZK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Headache
- Optune GioInjury
3010457505-2026-00895 · Received Oct 27, 2026 · Event dated Sep 29, 2026
Device type: Stimulator, Low Electric Field, Tumor Treatment (NZK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Laceration(s)
- Optune GioInjury
3010457505-2026-00894 · Received Oct 20, 2026 · Event dated Aug 28, 2026
Device type: Stimulator, Low Electric Field, Tumor Treatment (NZK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Skin Infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Optune Gio"[tiab]. The summary above synthesizes these.
- Case report: Safety of Tumor Treating Fields therapy with an implantable cardiac pacemaker in a patient with glioblastoma.
Biedermann GB, Merrifield K, Lustgarten L · Front Oncol · 2024Case Reports
- Use of tumor treating fields for a malignant brain tumor in a pregnant woman: Case report.
Rubisoier L, Lustgarten L, Thomé C, et al. · Brain Spine · 2026Case Reports
Other devices of this type
Also filed under product code NZK.
- OptuneNovocure, GmbH · PMA 2024
- Novocure GmbHs Optune GioNovocure, GmbH · PMA 2026
- Optune Gio - Maxpoint Version 2.0Novocure, GmbH · PMA 2025
- Novocure's Optune SystemNovocure, GmbH · PMA 2016
- NOVOTFF-100A SystemNovocure, GmbH · PMA 2014
- Novo TTF-100A SystemNovocure, GmbH · PMA 2014
- NOVOTTF-100A SystemNovocure, GmbH · PMA 2013
- Novocure NOVOTTF-100A SystemNovocure, GmbH · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.